Gout is the most common form of inflammatory arthritis, with a worldwide prevalence of approximately 4%. The accumulation of ...

A cheap gout medication, colchicine, shows significant promise in preventing heart attacks and strokes for individuals with ...

WASHINGTON, DC — Use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduced the need for urate-lowering therapy (ULT) and gout flare therapies in people who had both type 2 diabetes (T2D) and ...

A low dose of colchicine — a commonly used gout drug — helped reduce the risk of heart attack and stroke in people with ...

New findings that a common treatment for gout also cuts heart attacks adds weight to the idea that the 'plumbing' theory of ...

October 2, 2012 — New gout guidelines from the American College of Rheumatology are meant to improve gout management by providing clinicians with clear, readily implemented guidance on urate-lowering ...

A widely available drug used for gout may help prevent heart attacks and stroke in people with cardiovascular disease. | Drug ...

LONDON, June 8 (Reuters) - A drug used for more than 40 years to treat gout could also offer a cheap alternative to more modern heart drugs from Roche and Servier for patients with chronic chest pain, ...

A widely-used, inexpensive gout drug could reduce heart attacks and strokes in people with cardiovascular disease, according to a new Cochrane review. The review examined the effects of low doses of ...

For gout pain that does not respond to conventional therapies, patients’ only remaining option is a drug from Amgen. But this biologic medicine introduces the same problem facing every therapeutic ...

East Brunswick’s Savient Pharmaceuticals Inc. is starting the new year with a major boost. Savient’s chronic gout drug, Krystexxa, now has its own permanent billing code from the Centers for Medicare ...

* FDA "can not at this time" approve drug application * Seeks meeting with FDA * Seeks to resubmit application by early 2010 (Adds wording from letter in second paragraph) NEW YORK, Aug 2 (Reuters) - ...